Diabetic Neuropathy. Friedrich A. Gries
in type 2 diabetes in a Dutch population. Diabet Med 1991; 8: 435-8.
[29] Neeling JND De, Beks PJ, Bertelsmann FW, Heine RJ, Bouter LM. Peripheral somatic nerve function in relation to glucose tolerance in an elderly Caucasian population: the Hoorn Study. Diabet Med 1996; 13: 960-6.
[30] Müller UA, Ross IS, Klinger H. Häufigkeit der Hypopallästhesie bei insulinspritzenden Diabetikern in einer unausgewählten Stadtpopulation, Diab Stoffw 1993; 2: 439-42.
[31] Ziegler D, Gries FA, Mühlen H, Rathmann W, Spüler M, Lessmann F, the DiaCAN Multicenter Study Group. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. Diab Metab 1993; 19: 143-51.
[32] Veglio M, Sivieri R. Prevalence of neuropathy in IDDM patients in Piemonte, Italy. The Neuropathy Study Croup of the Italian Society for the Study of Diabetes. Piemonte Affiliate. Diabetes Care 1993; 16: 456-61.
[33] Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 89-94.
[34] Ratzmann KP, Raschke M, Gander B, Schimke P. Prevalence of peripheral and autonomic neuropathy in newly diagnosed type II (noninsulin dependent) diabetes. J Diab Complications 1991; 5: 1-5.
[35] Wang WQ, Ip TP, Lam KS. Changing prevalence of retinopathy in newly diagnosed non-insulin dependent diabetes mellitus patients in Hong Kong. Diabetes Res Clin Pract 1998; 39: 185-91.
[36] Gujral JS, McNally PG, O'Malley BP, Burden AC. Ethnic differences in the incidence of lower extremity amputation secondary to diabetes mellitus. Diabet Med 1993; 10: 271-4.
[37] Bharucha NE, Bharucha AE, Bharucha EP. Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology 1991; 41: 1315-7.
[38] Savettieri G, Rocca WA, Salemi G, Meneghini F, Grigoletto F, Morgante L, Reggio A, Costa V, Coraci MA, Di Perri R. Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Neurology 1993; 43: 1115-20.
[39] Watkins PJ. The natural history of the diabetic neuropathies. Q J Med 1990; 77: 1209-18.
[40] Eriksson KF, Nilsson H, Lindgärde F, Österlin S, Dahlin LB, Lilja B, Rosen I, Sundkvist G. Diabetes mellitus but not impaired glucose tolerance is associated with dysfunction of peripheral nerves. Diabet Med 1994; 11: 279-85.
[41] Sosenko JM, Kato M, Soto R, Goldberg RB. Sensory function at diagnosis and in early stages of NIDDM in patients detected through screening. Diabetes Care 1992; 15: 847-52.
[42] Sundkvist G, Dahlin L-B, Nilsson H, Eriksson K-F, Lindgärde F, Rosen I, Lattimer SA, Sima AAF, Sullivan K, Greene DA. Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance. Diabet Med 2000; 17: 259-68.
[43] Melton III LJ, Dyck PJ. Epidemiology. In: Dyck PJ, rhomas PK, Asbury AK, Winegrad AI, Porte D Jr, editors. Diabetic neuropathy. Philadelphia, Pa: W. B. Saunders; 1987: 27-35.
[44] Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 197DiabetesCare 1978; 252: 168-88.
[45] Töyry JP, Partanen JVS, Niskanen LK, Länsimies EA, Uusitupa MIJ. Divergent development of autonomic and peripheral somatic neuropathies in NIDDM. Diabetologia 1997; 40: 953-8.
[46] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
[47] Sands ML, Shetterly SM, Franklin GM, Hamman RF. Incidence of distal symmetric (sensory) neuropathy in NIDDM. San Luis Val Diabetes Study. Diabetes Care 1997; 20: 322-9.
[48] Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997; 49: 229-39.
[49] Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997; 46: 665-70.
[50] Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Fuller JH. Cardiovascular risk factors predict the development of diabetic peripheral neuropathy. Diabetes 2000; 49 (Suppl 1): A34.
[51] Hillson RM, Hockaday TDR, Newton DJ. Hyperglycaemia is one correlate of deterioration in vibration sense during the 5 years after diagnosis of type 2 (non-insulin-dependent) diabetes. Diabetologia 1984; 26: 122-6.
[52] Sosenko JM, Kato M, Soto R, Bild DE. A prospective study of sensory function in patients with type 2 diabetes. Diabet Med 1993; 10: 110-4.
[53] Young RJ, Macintyre CCA, Martyn CN, Prescott RJ, Ewing DJ, Smith AF, Viberti G, Clarke BF. Progression of subclinical polyneuropathy in young patients with type 1 (insulin-dependent) diabetes: associations with glycaemic control and microangiopathy (microvascular complications). Diabetologia 1986; 29: 156-61.
[54] Young RJ, Macintyre CCA, Ewing DJ, Prescott RJ. Prediction of neuropathy over 5 years in young insulin-dependent diabetic patients. Diabet Med 1988; 5: 7.
[55] Benbow SJ, Chan AW, Bowsher D, MacFarlane IA, Williams G. A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med 1994; 11: 17-21.
[56] Ziegler D, Piolot R. Prevention of diabetic neuropathy by near-normoglycemia. A 12-year prospective study from the diagnosis of IDDM. Diabetes 1998; 47 (Suppl 1): A63.
[57] Macleod AF, Till S, Sönksen PHS. Discussion of the clinical trials of the aldose reductase inhibitor tolrestat. Int Proc J 1991; 4: 17-24.
[58] Negrin P, Zara G. Conduction studies as prognostic parameters in the natural history of diabetic neuropathy: a long-term follow-up of 114 patients. Electromyogr Clin Neurophysiol 1995; 35: 341-50.
[59] Watanabe K, Hagura R, Akanuma Y, Takasu T, Kajinuma H, Kuzuya N, Irie M. Characteristics of cranial nerve palsies in diabetic patients. Diabetes Res Clin Pract 1990; 10: 19-27.
[60] Longstreth GF. Diabetic thoracic polyradiculopathy: ten patients with abdominal pain. Am J Gastroenterol 1997; 92: 502-5.
[61] Neil HA, Thompson AV, John S, McCarthy ST, Mann JI. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. Diabet Med 1989; 6: 20-4.
[62] Maser RE, Pfeifer MA, Dorman JS, Kuller LH, Becker DJ, Orchard TJ. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III. Arch Intern Med 1990; 150: 1218-22.
[63] O'Brien IAD, O'Hare JP, Lewin IG, Corrall RJM. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. Q J Med 1986; 61: 957-67.
[64] Stephenson J, Fuller JH, and EURODIAB IDDM Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study, Diabetologia 1994; 37: 278-85.
[65] Tsutsu N, Nunoi K, Yokomizo Y, Kikuchi M, Fujishima M. Relationship between glycemic control and orthostatic hypotension in type 2 diabetes mellitus–a survey by the Fukuoka Diabetes Clinic Group. Diabetes Res Clin Pract 1990; 8: 115-23.
[66] Ziegler D, Dannehl K, Spüler M, Mühlen H, Gries FA. Prevalence of cardiovascular autonomic nerve dysfunction assessed by spectral analysis and standard tests of heart rate variation in newly diagnosed IDDM patients. Diabetes Care 1992; 15: 908-11.
[67] Lehtinen JM, Uusitupa